Package Leaflet: Information for the User
Olanzapine Apotex 2.5 mg film-coated tablets EFG
Olanzapine Apotex 5 mg film-coated tablets EFG
Olanzapine Apotex 7.5 mg film-coated tablets EFG
Olanzapine Apotex 10 mg film-coated tablets EFG
Olanzapine
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
Olanzapine Apotex contains the active ingredient olanzapine. Olanzapine Apotex belongs to a group of medications called antipsychotics and is indicated for the treatment of the following diseases.
Olanzapine Apotex has been shown to prevent the recurrence of these symptoms in patients with bipolar disorder whose manic episodes have responded to treatment with olanzapine.
Do not take Olanzapine Apotex
Warnings and Precautions
Consult your doctor or pharmacist before starting to take Olanzapine Apotex.
If you have any of the following diseases, inform your doctor as soon as possible:
If you suffer from dementia, you or your caregiver or family member should inform your doctor if you have ever had a stroke or a lack of blood flow to the brain.
As a routine precaution, if you are over 65 years old, it would be advisable for your doctor to check your blood pressure.
Children and Adolescents
Patients under 18 years of age should not take Olanzapine Apotex.
Using Olanzapine Apotex with Other Medications
Use other medications at the same time as Olanzapine Apotex only if your doctor authorizes it. You may feel drowsy if you combine Olanzapine Apotex with antidepressants or medications for anxiety or that help you sleep (tranquilizers).
Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medication.
In particular, tell your doctor if you are taking:
Using Olanzapine Apotex with Alcohol
Do not drink alcohol if you have been given Olanzapine Apotex, as the combination of Olanzapine Apotex and alcohol may cause drowsiness.
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medication. You should not take this medication while breastfeeding, as small amounts of Olanzapine Apotex may pass into breast milk.
The following symptoms may occur in newborns of mothers who have used Olanzapine Apotex in the last trimester (last three months of pregnancy): tremors, muscle stiffness and/or weakness, drowsiness, agitation, respiratory problems, and difficulty eating. If your baby has any of these symptoms, contact your doctor.
Driving and Using Machines
There is a risk of drowsiness when taking Olanzapine Apotex. If this happens to you, do not drive vehicles or use machinery. Consult your doctor.
Olanzapine Apotex Contains Lactose
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow the administration instructions of this medication exactly as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
Your doctor will tell you how many Olanzapine Apotex tablets to take and for how long. The daily dose of Olanzapine Apotex ranges from 5 mg to 20 mg. Consult your doctor if you experience symptoms again, but do not stop taking Olanzapine Apotex unless your doctor tells you to.
You should take your Olanzapine Apotex tablets once a day, following your doctor's instructions. Try to take the tablets at the same time every day. You can take them with or without food.
The film-coated tablets of Olanzapine Apotex are for oral administration. You should swallow the Olanzapine Apotex tablets whole with water.
If You Take More Olanzapine Apotex Than You Should
Patients who have taken more Olanzapine Apotex than they should have experienced the following symptoms: rapid heartbeat, agitation/aggression, speech problems, unusual movements (especially of the face and tongue), and a reduced level of consciousness. Other symptoms may include: acute confusion, seizures (epilepsy), coma, a combination of fever, rapid breathing, sweating, muscle stiffness, and a state of confusion or drowsiness, slowing of respiratory rate, aspiration, increased or decreased blood pressure, and abnormal heart rhythms. Contact your doctor or go to the hospital immediately if you notice any of the above symptoms. Show the doctor the package with the tablets.
If You Forget to Take Olanzapine Apotex
Take your tablets as soon as you remember. Do not take a double dose to make up for forgotten doses.
If You Stop Taking Olanzapine Apotex
Do not stop treatment just because you feel better. It is important that you continue taking Olanzapine Apotex while your doctor tells you to.
If you stop taking Olanzapine Apotex suddenly, symptoms such as sweating, insomnia, tremors, anxiety, or nausea and vomiting may appear. Your doctor may suggest that you gradually reduce the dose before stopping treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone gets them.
Contact your doctor immediately if you have:
Very common side effects (which can affect more than 1 in 10 people) include weight gain, drowsiness, and increased prolactin levels in the blood. In the early stages of treatment, some people may feel dizzy or faint (with slower heartbeats), especially when getting up from a lying or sitting position. This feeling usually disappears on its own, but if it does not, consult your doctor.
Common side effects (which can affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating lipids, and temporary increases in liver enzymes at the start of treatment, increased blood sugar and urine levels, increased uric acid and creatine phosphokinase levels in the blood, increased appetite, dizziness, agitation, tremors, unusual movements (dyskinesia), constipation, dry mouth, skin rash, loss of strength, excessive fatigue, fluid retention that causes swelling of the hands, ankles, or feet, fever, joint pain, and sexual dysfunction such as decreased libido in men and women or erectile dysfunction in men.
Uncommon side effects (which can affect up to 1 in 100 people) include hypersensitivity (e.g., inflammation of the mouth and throat, itching, skin rash), diabetes or worsening of diabetes, occasionally related to ketoacidosis (acetone in blood and urine) or coma, seizures, mostly related to a history of seizures (epilepsy), muscle stiffness or spasms (including eye movements), restless legs syndrome, speech problems, stuttering, slow pulse, sensitivity to sunlight, nosebleeds, abdominal distension, excessive salivation, memory loss or forgetfulness, urinary incontinence, loss of urination ability, hair loss, absence or decrease of menstrual periods, and changes in the mammary gland in men and women, such as abnormal milk production or abnormal growth.
Rare side effects (which can affect up to 1 in 1,000 people) include a drop in normal body temperature, abnormal heart rhythm, sudden unexplained death, pancreatitis, which causes severe stomach pain, fever, and discomfort, liver disease, with yellowing of the skin and the white parts of the eyes, muscle disorder that presents as unexplained pain and erectile dysfunction that is prolonged and/or painful.
Very rare side effects include a severe allergic reaction such as drug reaction with eosinophilia and systemic symptoms (DRESS). DRESS is initially manifested by flu-like symptoms with a rash on the face and then a generalized rash, fever, lymph node enlargement, elevated liver enzyme levels in blood tests, and an increase in the number of a type of white blood cell (eosinophilia).
During treatment with olanzapine, elderly patients with dementia may experience stroke, pneumonia, urinary incontinence, falls, extreme fatigue, visual hallucinations, a rise in body temperature, redness of the skin, and walking problems. Some deaths have been reported in this particular group of patients.
Olanzapine Apotex may worsen symptoms in patients with Parkinson's disease.
Reporting Side Effects
If you experience any side effects, consult your doctor or nurse, even if they are not listed in this package leaflet. You can also report them directly through the national reporting system included in Annex V. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date stated on the package and blister after EXP. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medications should not be disposed of through wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Composition of Olanzapine Apotex
The active ingredient is olanzapine.
The other ingredients (tablet core) are lactose monohydrate, microcrystalline cellulose, cornstarch, magnesium stearate, (tablet coating) hypromellose, hydroxypropylcellulose, macrogol 8000, titanium dioxide (E171).
Appearance of the Product and Package Contents
Only some pack sizes may be marketed.
Marketing Authorization Holder
Apotex Europe B.V.
Archimedesweg 2,
2333 CN, Leiden,
Netherlands
Manufacturer:
Generis Farmacêutica, S.A.
Rua João de Deus, 19
2700-48 Amadora
Portugal
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Belgium NV Apotex SA Tel: (32) 475.35.40 | Luxembourg NV Apotex SA Tel: (32) 475.35.40 |
Hungary Apotex Europe B.V. Tel: (31) 71. 565.77. 77 | |
Czech Republic Aurovitas, spol. s r.o. Tel: (420) 234.705.721 | Malta Apotex Europe B.V. Tel: (31) 71. 565.77.77 |
Denmark Apotex Europe B.V. Tel: (31) 71. 565.77. 77 | Netherlands Apotex Nederland B.V. Tel: (31) 71. 52.43.100 |
Germany Apotex Europe B.V. Tel: (31) 71. 565.77. 77 | Norway Apotex Europe B.V. Tel: (31) 71. 565.77. 77 |
Estonia Apotex Europe B.V. Tel: (31) 71. 565.77. 77 | Austria Apotex Europe B.V. Tel: (31) 71. 565.77. 77 |
Greece Apotex Europe B.V. Tel: (31) 71. 565.77. 77 | Poland Aurovitas Pharma Polska Sp. z o.o. Tel: (048) 22.311.20.00 |
Spain Aurovitas Spain, S.A.U. Tel: (34) 91.630.86.45 | Portugal Apotex Europe B.V. Tel: (31) 71. 565.77. 77 |
France NV Apotex SA Tel: (32) 475.35.40 Croatia Apotex Europe B.V. Tel: (31) 71. 565.77.77 | Romania Apotex Europe B.V. Tel: (31) 71. 565.77. 77 |
Ireland Apotex Europe B.V. Tel: (31) 71. 565.77.77 | Slovenia Apotex Europe B.V. Tel: (31) 71. 565.77. 77 |
Iceland Apotex Europe B.V. Tel: (31) 71. 565.77. 77 | Slovakia Apotex Europe B.V. Tel: (31) 71. 565.77. 77 |
Italy Apotex Europe B.V. Tel: (31) 71. 565.77. 77 | Finland Apotex Europe B.V. Tel: (31) 71. 565.77. 77 |
Cyprus Apotex Europe B.V. Tel: (31) 71. 565.77. 77 | Sweden Apotex Europe B.V. Tel: (31) 71. 565.77. 77 |
Latvia Apotex Europe B.V. Tel: (31) 71. 565.77. 77 | United Kingdom Apotex Europe B.V. Tel: (31) 71. 565.77.77 |
Lithuania Apotex Europe B.V. Tel: (31) 71. 565.77. 77 |
Date of the Last Revision of this Leaflet:
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.